Prostate cancer Board decisions

The Board found that the cause of death was metastatic prostate cancer, which is not service-connected. The veteran's service-connected bilateral knee disability did not contribute to his death. Therefore, the claim for service connection for the cause of death and DIC under 38 U.S.C.A. § 1318 were both denied.

The veteran's appeal for restoration of a 100 percent rating and request for a higher rating than 60 percent for prostate cancer was denied. The RO reduced his rating to 60 percent in September 2003, based on the absence of local recurrence or metastasis.

The Board has remanded the case due to a lack of verification regarding the veteran's exposure along the DMZ in Korea, and thus service connection for prostate cancer cannot be determined at this time.

The Board denied the veteran's claims for service connection for prostate cancer and a skin disorder, as well as his request for an increased evaluation for diabetes mellitus. The severance of service connection for diabetes mellitus was also denied.

The veteran's claims for service connection for prostate cancer and right shoulder injury residuals were denied. The Board found no current evidence of these conditions, and the claim for new and material evidence regarding cervical and low back injuries was also denied.

The veteran's death was not caused by any service-connected condition, and the appellant is denied benefits for accrued benefits and DEA eligibility.

The veteran's claims for service connection for colon and prostate cancers due to exposure to ionizing radiation were denied as there was no evidence of such exposure, and the diseases did not manifest within one year of separation from service.

The Board denied the veteran's claims for service connection for prostate cancer and gall bladder cancer, finding no evidence of a nexus between these conditions and his military service.

The Board granted service connection for prostate cancer effective June 27, 2002. The veteran's claim for an earlier effective date was also granted.

The Board denied the veteran's claim for compensation under 38 U.S.C.A. § 1151 for the cause of his death due to prostate cancer, concluding that the removal of the medication Casodex did not hasten his death and attributing his condition to the incurable nature of metastatic prostatic cancer.

The Board has reopened the claim for service connection for residuals of prostate cancer due to new and material evidence. However, further development is needed before these claims can be decided on their merits.

The veteran's prostate cancer, right eye injury residuals, and hearing loss were not found to be related to service or exposure to ionizing radiation.

The veteran's claim for an initial combined rating in excess of 40 percent for residuals of prostate cancer, to include voiding dysfunction and impotence, is being remanded due to the need for additional development.

The veteran has withdrawn his appeal for a higher initial evaluation for residuals of prostate cancer surgery from April 16, 2003.

The Board denied the veteran's claims for higher initial ratings for residuals of prostate cancer, finding that he did not meet the criteria for a rating higher than 10 percent prior to November 28, 2005 or higher than 20 percent since then.

The veteran's appeal has been dismissed due to his death before a final decision could be made.

The Board denied service connection for the cause of the veteran's death, finding that his service-connected disabilities did not cause or contribute to his death.

The Board denied service connection for the cause of the veteran's death and denied DIC benefits under 38 U.S.C.A. § 1318 due to lack of evidence linking the cause of death to his military service or any service-connected disability.

The Board denied the veteran's claims for increased ratings for prostate cancer residuals with impotency, finding that the evidence did not support a rating higher than 20 percent prior to May 4, 2006 and 40 percent from May 4, 2006 forward.

The VA denied the veteran's claim for service connection for prostate cancer, attributing it to a lack of evidence showing exposure to herbicide agents during his military service and no medical relationship between the condition and service.